Cara Therapeutics (CARA) Misses Q2 EPS by 6c

Cara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.48), $0.06 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $79 thousand versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue
• Beike (BEKE) PT Raised to $23 at Morgan Stanley